-
This is default featured slide 1 title
Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
-
GMP Trends, Quality Tools
Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
-
GMP News drifts on Market and economy
Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
-
This is default featured slide 4 title
Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.
-
What to Ask Your Doctor Before Taking Opioids
Every patient should ask questions when getting a new prescription. This is especially important when your doctor, dentist or other health care professional prescribes you an opioid, such as hydrocodone, oxycodone, codeine and morphine. What should you ask?
Sunday, January 29, 2017
Importance of Corrective action and Preventive action (CAPA) FDA Warning Letter on GMP Violations
Monday, January 23, 2017
“Effective CAPA System”- An assurance to “Acceptable-State-of-Control” of QMS
“Corrective Action” was the term first incepted by the US Government during the second world war to address nonconforming material in “Military Standard 1520”. Primarily, the focus of military standard was to standardize the method on nonconforming material and their dispositions, subsequently retitled as “Corrective and preventive action” (CAPA) and now recognized to be a fundamental prerequisite in order to ensure healthy functioning of “Quality Management system’.
- ISO 9001 & 13485: Quality Management System, clause
8.5.2 & 8.5.3.
- CDSCO-India: Schedule M- good
manufacturing practices and requirements of premises, plant and equipment
for pharmaceutical products, clauses 15.1 to 15.3 & 24.2.
- ICH-Q7 on “Good
manufacturing practice guide for active pharmaceutical ingredients”,
clause 2.41, 2.50, 2.51, 11.15 & 15.12.
- 21 CFR Part 211-current good manufacturing practice for finished
pharmaceuticals, clause 211.22 & 211.92.
- U.S.
Food and Drug Administration’s regulation governing medical device
manufacturers quality systems: 21 CFR Part 820.100.
- USFDA: Guidance for Industry-Quality Systems Approach to
Pharmaceutical CGMP Regulations, clause III- C & D , IV-D (4 & 6)
& glossary.
- WHO-Good
manufacturing practices for pharmaceutical products: main principles,
TRS-961, Annex-3.
- USFDA-Guidance
for Industry on “Investigating Out-of-Specification (OOS) Test Results for
Pharmaceutical Production”, clause Phase-I (b), Phase-II (a) & V.
- MHRA-Guidance
document on “Out Of Specification Investigations”, clause Phase-II &
III.
- ICH-Q8: Pharmaceutical development, clause- appendix-I (life
cycle management).
- ICH-Q9: Quality Risk Management, clause 1.5, I.3, I.5, II.4
& II.7.
- ICH-Q10: Pharmaceutical Quality System, clause 1.7 (f), 3.2.1
(a), 3.2.2 (Table-II), 3.2.4 (a) & glossary.
- Defining
the problem or non-conformity, what?
- Define
the cause of the problem, why? i.e. RCA
- Developing
an action plan to correct the problem and prevent a recurrence? Identify-
CA
- Define the potential problem or nonconformance?
What(Potential)
- Define
the cause of the potential problem? Why (Potential)
- Developing
an action plan to prevent the potential problem to avert occurrence?
Identify potential -PA
- Implementing
the plan? Execute the potential -PA
- Ensure
the completion of CA V/s PA as planned.
- Effectiveness
of CA/PA can be based on predefined -number of batches versus period.
- Examine
the recurring issues, if any and why? Is it really due to this CA?
- While
it is subjective in terms of succession criteria as number of successful
batches , this may include further into micro level evaluation on to see
the degree of improvement as
Author: Sanjeev Kumar Singh
Deputy General Manager - Corporate Quality Assurance at
Mylan Laboratories Limited
www.gmpviolations.com
GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.) Disclaimer: The Logos/Images posted here are belongs to respective to Authority / owners of firm.
Sunday, January 22, 2017
Understanding CAPA by James Bullock, PMP, ASQ CMQ/OE, CSSGB
- A correction is an immediate one-time action to
fix a non-conformity. This can be classified as rework or a repair having
little risk or impact which is typically completed informally.
- A corrective action is an action taken to
eliminate or reduce the cause and recurrence of a nonconformity or other
undesirable event which poses greater risk and is formally completed
(there is action taken after there is a failure).
- Preventive actions eliminate or reduce a
nonconformity or undesirable event by averting their occurrence (A failed
event has not occurred yet, but there are actions taken to stop a failure
or nonconformity from happening). Preventive action(s) can result from an
effective corrective action or through continuous risk identification
during any stage where changes are made as applicable to processes,
systems, etc., to eliminate, avoid, or reduce the occurrence of issues
leading to poor quality.
www.gmpviolations.com GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.) Disclaimer: The Logos/Images posted here are belongs to respective to Authority / owners of firm.












